Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02668367 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers
A Phase 1 study, sponsored by Biota Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02668367: Completed Phase 1 study, sponsored by Biota Pharmaceuticals.
NCT02668367 is a Phase 1 study that has completed, run by Biota Pharmaceuticals. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02668367, a Phase 1 study, has completed, sponsored by Biota Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.
Interventions
- DRUG BTA-C585 oral capsules
- DRUG BTA-C585 matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02668367
The ClinicalTrials.gov registry entry for NCT02668367 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biota Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BTA-C585 oral capsules is the first listed.
NCT02668367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02668367 about?
NCT02668367 is a clinical study titled "Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers". This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.
What is the current status of trial NCT02668367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-11. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02668367?
The interventions under investigation include: BTA-C585 oral capsules (DRUG), BTA-C585 matching placebo (DRUG).
Who is sponsoring clinical trial NCT02668367?
This trial is sponsored by Biota Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.